Aromatase Inhibitor-Induced Arthralgia Among Patients With Early Breast Cancer: Prevalence, Treatment Nonadherence, and Management in a Prospective Longitudinal Cohort.

Date publication

février 2026

Journal

Journal of the National Comprehensive Cancer Network : JNCCN

Auteurs

Membres identifiés du Cancéropôle Est :
Dr JOUANNAUD Christelle

Tous les auteurs :
Lapidari P, Lustberg MB, Havas J, Pagliuca M, Franzoi MA, Menvielle G, Pistilli B, Jouannaud C, Sauterey B, Tredan O, Cottu PH, Cherifi F, Lerebours F, Gaudin C, Martin AL, Vaz-Luis I, Di Meglio A

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/41698329

Résumé

Aromatase inhibitor (AI)-induced arthralgia (AIA) can lead to treatment discontinuation and worse disease outcomes. This study assessed the prevalence of AIA, nonadherence to AI therapy, and supportive care strategies (SCS) among patients with early-stage breast cancer.

Référence

J Natl Compr Canc Netw. 2026 02 10;:1-12